Hypersensitivity of ERCC1 and XPF mutant cells to crosslinking anti‐cancer drugs is well documented (McHugh et al, 2001); however, whether SNM1A‐deficient cells recapitulate this sensitivity is unknown. Here, ERCC1 is linked to cancer.